Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Radioimmunotherapy As the First Line of Treatment in Non-Hodgkin Lymphoma Publisher Pubmed



Eskian M1, 2 ; Khorasanizadeh M1, 2 ; Zinzani PL3 ; Rezaei N1, 4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, Research Center for Immunodeficiencies, Children's Medical Center Hospital, Tehran University of Medical Sciences Dr. Qarib St, Keshavarz Blvd, Tehran, 14194, Iran
  2. 2. Department of Immunology, Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, 14194, Iran
  3. 3. Department of Hematology and Oncological Sciences 'L. e A. Seragnoli, University of Bologna, Bologna, 40138, Italy
  4. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, 14194, Iran
  5. 5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Boston, MA, United States

Source: Immunotherapy Published:2018


Abstract

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy. The estimated deaths and new cases of NHL in the USA in 2018 have reached 19,910 and 74,680, respectively, with 5-year survival rate of 71%. Therapeutic interventions for NHL consist of chemotherapy, radiation therapy and immunotherapy. Radioimmunotherapy (RIT) is a potential alternative treatment for NHL that is currently used in different lines of treatment. Studies show that nuclear medicine physicians and radiation oncologists are not yet certain about the proper line for administration of RIT. Herein, we have reviewed the efficiency and toxicity of RIT as the first line of treatment, and discussed potential novel indications, and strategies such as modifying induction therapy and using rituximab maintenance to optimize the efficiency of RIT as the first line of treatment. Our review indicates that it is more logical to postpone conventional therapies to the second or third lines of treatment instead of RIT. © 2018 Future Medicine Ltd.
Related Docs
1. Radioimmunotherapy in Non-Hodgkin Lymphoma: Prediction and Assessment of Response, Critical Reviews in Oncology/Hematology (2016)
2. Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma, International Reviews of Immunology (2019)
3. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
4. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)
5. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
6. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
7. The Promising Role of Monoclonal Antibodies for Immunotherapy of the Hiv-Associated Cancer, Non-Hodgkin Lymphoma, International Reviews of Immunology (2018)
8. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
Experts (# of related papers)
Nima Rezaei (6)